Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. 2001

Sally Sharpe, and Natasha Polyanskaya, and Mike Dennis, and Gerd Sutter, and Tomáš Hanke, and Volker Erfle, and Vanessa Hirsch, and Martin Cranage
Centre for Applied Microbiology and Research (CAMR), Salisbury SP4 0JG, UK1.

A major aim in AIDS vaccine development is the definition of strategies to stimulate strong and durable cytotoxic T lymphocyte (CTL) responses. Here we report that simian immunodeficiency virus (SIV)-specific CTL developed in 4/4 macaques following a single intramuscular injection of modified vaccinia virus Ankara (MVA) constructs expressing both structural and regulatory/accessory genes of SIV. In two animals Nef-specific responses persisted, but other responses diminished and new responses were not revealed, following further vaccination. Vaccination of another two macaques, expressing Mamu A*01 MHC class I, with MVA constructs containing nef and gag-pol under the control of the moderate strength natural vaccinia virus early/late promoter P7.5, again induced an early Nef-specific response, whereas responses to Gag remained undetectable. Anti-vector immunity induced by this immunization was shown to prevent the efficient stimulation of CTL directed to the cognate Gag epitope, p11C C-M, following vaccination with another MVA construct expressing SIV Gag-Pol under a strong synthetic vaccinia virus-specific promoter. In contrast, vaccination of a previously unexposed animal resulted in a SIV-specific CTL response widely disseminated in lymphoid tissues including lymph nodes associated with the rectal and genital routes of SIV entry. Thus, despite the highly attenuated nature of MVA, repeated immunization may elicit sufficient anti-vector immunity to limit the effectiveness of later vaccination.

UI MeSH Term Description Entries
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014616 Vaccinia virus The type species of ORTHOPOXVIRUS, related to COWPOX VIRUS, but whose true origin is unknown. It has been used as a live vaccine against SMALLPOX. It is also used as a vector for inserting foreign DNA into animals. Rabbitpox virus is a subspecies of VACCINIA VIRUS. Buffalopox virus,Poxvirus officinale,Rabbitpox virus,Buffalo Pox Virus,Rabbit Pox Virus,Buffalo Pox Viruses,Buffalopox viruses,Rabbit Pox Viruses,Rabbitpox viruses,Vaccinia viruses,Virus, Buffalo Pox,Viruses, Buffalo Pox,virus, Buffalopox
D015302 Simian Immunodeficiency Virus Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV. SIV (Simian immunodeficiency virus),Immunodeficiency Viruses, Simian,Simian Immunodeficiency Viruses,Immunodeficiency Virus, Simian
D015683 Gene Products, gag Proteins coded by the retroviral gag gene. The products are usually synthesized as protein precursors or POLYPROTEINS, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. gag is short for group-specific antigen. Viral gag Proteins,gag Antigen,gag Gene Product,gag Gene Products,gag Polyproteins,gag Protein,gag Viral Proteins,Gene Product, gag,Retroviral Antigen gag Protein,gag Antigens,gag Gene Related Protein,gag Polyprotein,Antigen, gag,Antigens, gag,Polyprotein, gag,Polyproteins, gag,Protein, gag,Proteins, Viral gag,Proteins, gag Viral,Viral Proteins, gag,gag Proteins, Viral
D015685 Fusion Proteins, gag-pol Polyprotein products of a fused portion of retroviral mRNA containing the gag and pol genes. The polyprotein is synthesized only five percent of the time since pol is out of frame with gag, and is generated by ribosomal frameshifting. gag-pol Fusion Proteins,gag-pol Protein,gag-pol Fused Protein,Fused Protein, gag-pol,Fusion Proteins, gag pol,Protein, gag-pol,Protein, gag-pol Fused,Proteins, gag-pol Fusion,gag pol Fused Protein,gag pol Fusion Proteins,gag pol Protein
D019076 Transgenes Genes that are introduced into an organism using GENE TRANSFER TECHNIQUES. Recombinant Transgenes,Recombinant Transgene,Transgene,Transgene, Recombinant,Transgenes, Recombinant

Related Publications

Sally Sharpe, and Natasha Polyanskaya, and Mike Dennis, and Gerd Sutter, and Tomáš Hanke, and Volker Erfle, and Vanessa Hirsch, and Martin Cranage
March 2000, Journal of virology,
Sally Sharpe, and Natasha Polyanskaya, and Mike Dennis, and Gerd Sutter, and Tomáš Hanke, and Volker Erfle, and Vanessa Hirsch, and Martin Cranage
May 1995, Journal of immunology (Baltimore, Md. : 1950),
Sally Sharpe, and Natasha Polyanskaya, and Mike Dennis, and Gerd Sutter, and Tomáš Hanke, and Volker Erfle, and Vanessa Hirsch, and Martin Cranage
March 2000, Journal of virology,
Sally Sharpe, and Natasha Polyanskaya, and Mike Dennis, and Gerd Sutter, and Tomáš Hanke, and Volker Erfle, and Vanessa Hirsch, and Martin Cranage
June 2001, Journal of virology,
Sally Sharpe, and Natasha Polyanskaya, and Mike Dennis, and Gerd Sutter, and Tomáš Hanke, and Volker Erfle, and Vanessa Hirsch, and Martin Cranage
October 2016, Journal of virology,
Sally Sharpe, and Natasha Polyanskaya, and Mike Dennis, and Gerd Sutter, and Tomáš Hanke, and Volker Erfle, and Vanessa Hirsch, and Martin Cranage
September 1999, Journal of virology,
Sally Sharpe, and Natasha Polyanskaya, and Mike Dennis, and Gerd Sutter, and Tomáš Hanke, and Volker Erfle, and Vanessa Hirsch, and Martin Cranage
April 2007, Journal of medical primatology,
Sally Sharpe, and Natasha Polyanskaya, and Mike Dennis, and Gerd Sutter, and Tomáš Hanke, and Volker Erfle, and Vanessa Hirsch, and Martin Cranage
June 1996, Journal of virology,
Sally Sharpe, and Natasha Polyanskaya, and Mike Dennis, and Gerd Sutter, and Tomáš Hanke, and Volker Erfle, and Vanessa Hirsch, and Martin Cranage
October 2014, The Journal of general virology,
Sally Sharpe, and Natasha Polyanskaya, and Mike Dennis, and Gerd Sutter, and Tomáš Hanke, and Volker Erfle, and Vanessa Hirsch, and Martin Cranage
May 2001, Vaccine,
Copied contents to your clipboard!